|Bid||81.16 x 1400|
|Ask||81.13 x 900|
|Day's range||81.00 - 81.82|
|52-week range||75.77 - 114.31|
|Beta (5Y monthly)||0.73|
|PE ratio (TTM)||35.97|
|Forward dividend & yield||2.72 (3.14%)|
|Ex-dividend date||20 Dec 2022|
|1y target est||N/A|
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced Cosmo Pharmaceuticals and NVIDIA plan to integrate NVIDIA's AI technologies into the GI Genius™ intelligent endoscopy module — the first FDA-cleared, AI-assisted colonoscopy tool to help physicians detect polyps that can lead to colorectal cancer.
Medtronic (NYSE:MDT) announced today that it has received CE (Conformité Européenne) Mark for the Affera™ Mapping and Ablation System, which includes the Sphere-9™ Catheter and the Affera™ Prism-1 Mapping Software. Together, the full system creates a new paradigm in electrophysiology through the unique integration of the Sphere-9 pulsed field ablation (PFA), radiofrequency (RF), and high density (HD) mapping catheter, which maps and ablates atrial arrhythmias (fast, abnormal heart rhythms) and p
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has been recognized by Ethisphere, a leader in defining and advancing the standards of ethical business practices, as one of the 2023 World's Most Ethical Companies. In 2023, 135 honorees were recognized spanning 19 countries and 46 industries. Medtronic is one of only two honorees in the 'Healthcare Products' industry category.